Market Closed -
Australian S.E.
01:52:47 2024-05-02 am EDT
5-day change
1st Jan Change
0.096
AUD
-4.00%
-45.14%
-61.60%
Presentation Operator MessageOperator (Operator)Thank you for standing by, and welcome to the ...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Transcript : Visioneering Technologies, Inc., Q1 2024 Earnings Call, Apr 23, 2024
Apr. 23
Visioneering Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 28
CI
Visioneering Technologies Releases One-Year Data from Myopia Progression Control Study
Jan. 18
MT
Visioneering Technologies Issues Part of Shortfall from Rights Offering
Jan. 04
MT
Transcript : Visioneering Technologies, Inc. - Shareholder/Analyst Call
Nov. 01
Transcript : Visioneering Technologies, Inc., Q3 2023 Earnings Call, Oct 18, 2023
23-10-18
Visioneering Technologies Raising Funds for Clinical Trial, Business Expansion
23-10-10
MT
Visioneering Technologies Appoints CEO
23-08-28
MT
Visioneering Technologies, Inc. Announces the Appointment of Juan Carlos Aragón as Chief Executive Officer, Effective 1 October 2023
23-08-28
CI
Visioneering Technologies, Inc. Announces the Appointment of Juan Carlos Aragón as Executive Director, Effective 1 October 2023
23-08-28
CI
Visioneering Technologies, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-16
CI
Transcript : Visioneering Technologies, Inc., Q2 2023 Earnings Call, Jul 21, 2023
23-07-20
Transcript : Visioneering Technologies, Inc. - Shareholder/Analyst Call
23-05-24
Transcript : Visioneering Technologies, Inc., Q1 2023 Earnings Call, Apr 20, 2023
23-04-19
Visioneering Technologies Says Exposure to Collapsed Silicon Valley Bank is Minimal
23-03-12
MT
Visioneering Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
23-02-27
CI
Visioneering Technologies, Inc. Announces Board Changes
22-12-19
CI
Visioneering Technologies Hits 100% Enrollment Milestone for NaturalVue Multifocal Contact Lens Trial
22-12-07
MT
Visioneering Technologies, Inc. Enrolls 100% of Subjects in its International Randomized Controlled Clinical Trial Known as PROTECT
22-12-06
CI
Transcript : Visioneering Technologies, Inc. - Shareholder/Analyst Call
22-10-26
Visioneering Technologies, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
22-08-22
CI
Transcript : Visioneering Technologies, Inc., Q2 2022 Earnings Call, Jul 20, 2022
22-07-20
Visioneering Technologies Reaches 50% Enrolment Milestone in Nearsightedness Clinical Trial
22-07-12
MT
Visioneering Technologies, Inc. Achieves 50% Enrollment Milestone in its PROTECT International Clinical Study for Myopia Progression Control
22-07-12
CI
Visioneering Technologies, Inc. Announces Board Changes
22-06-29
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Visioneering Technologies, Inc. is a medical device company. The Company is primarily engaged in the design, manufacture, sale and distribution of a contact lens, the NaturalVue Multifocal 1 Day (NaturalVue MF) contact lens. The Company operates through two segments: North America and Europe / Asia-Pacific. The North America segment includes its operations in the United States and Canada. The Europe/Asia-Pacific segment includes its operations outside of North America. Its flagship product is the NaturalVue (etafilcon A) Multifocal 1 Day Contact Lens for adults with Presbyopia and children with Myopia. The Company sells its contact lenses in the United States, Europe, Australia, New Zealand, Hong Kong, Singapore, Canada and Malaysia. The Company manages the warehousing and distribution of its products through a contract with a third-party logistics provider (the 3PL).
More about the company
1st Jan change
Capi.
-61.60% 3.47M +10.41% 97.27B -5.14% 17.84B -16.61% 2.33B -12.77% 1.46B +32.16% 1.28B -34.97% 755M -36.42% 740M -7.58% 669M +25.66% 515M
Glasses, Spectacles & Contact Lenses
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1